237 related articles for article (PubMed ID: 15792738)
21. [Gram-positive bacterial infections resistant to antibiotic treatment].
Utili R
Ann Ital Med Int; 2001; 16(4):205-19. PubMed ID: 11799629
[TBL] [Abstract][Full Text] [Related]
22. Gram-positive resistance: challenge for the development of new antibiotics.
Baquero F
J Antimicrob Chemother; 1997 May; 39 Suppl A():1-6. PubMed ID: 9511055
[TBL] [Abstract][Full Text] [Related]
23. Antibacterial activity of LCB01-0062, a novel oxazolidinone.
Jung SJ; Yun IN; Park HS; Lee HH; Jeong JW; Kim YZ; Cho YL; Kwak JH
Int J Antimicrob Agents; 2012 Dec; 40(6):539-43. PubMed ID: 23058227
[TBL] [Abstract][Full Text] [Related]
24. Antimicrobial resistance in gram-positive bacteria.
Rice LB
Am J Infect Control; 2006 Jun; 34(5 Suppl 1):S11-9; discussion S64-73. PubMed ID: 16813977
[TBL] [Abstract][Full Text] [Related]
25. Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria.
Appelbaum PC; Jacobs MR
Curr Opin Microbiol; 2005 Oct; 8(5):510-7. PubMed ID: 16098786
[TBL] [Abstract][Full Text] [Related]
26. Spectrum of gram-positive bacteraemia and in vitro activities of daptomycin, linezolid and vancomycin against organisms isolated from cancer patients.
Rolston KV; Kapadia M; Tarrand J; Coyle E; Prince RA
Int J Antimicrob Agents; 2013 Jun; 41(6):516-20. PubMed ID: 23481658
[TBL] [Abstract][Full Text] [Related]
27. Emerging issues in the diagnosis and management of infections caused by multi-drug-resistant, gram-positive cocci.
Napolitano LM
Surg Infect (Larchmt); 2005; 6 Suppl 2():S-5-22. PubMed ID: 23577494
[TBL] [Abstract][Full Text] [Related]
28. In-vitro activity of quinupristin/dalfopristin (Synercid) against isolates of Streptococcus pneumoniae, Staphylococcus aureus and enterococcus spp.
Johnson AP; Warner M; Speller DC
J Antimicrob Chemother; 1997 Oct; 40(4):604-5. PubMed ID: 9372437
[No Abstract] [Full Text] [Related]
29. Analysis of Gram-positive bacterial infection in patients following liver transplantation.
Li H; Yu DL; Ren L; Zhong L; Peng ZH; Teng MJ
Chin Med J (Engl); 2012 Jul; 125(14):2417-21. PubMed ID: 22882913
[TBL] [Abstract][Full Text] [Related]
30. Perspectives on the development of new antimicrobial agents for resistant gram-positive pathogens.
Jones RN
Braz J Infect Dis; 2000 Feb; 4(1):1-8. PubMed ID: 10950626
[TBL] [Abstract][Full Text] [Related]
31. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).
Sader HS; Watters AA; Fritsche TR; Jones RN
BMC Infect Dis; 2007 Apr; 7():29. PubMed ID: 17442104
[TBL] [Abstract][Full Text] [Related]
32. In vitro activity of linezolid & quinupristin/dalfopristin against Gram-positive cocci.
Tünger A; Aydemir S; Uluer S; Cilli F
Indian J Med Res; 2004 Dec; 120(6):546-52. PubMed ID: 15654141
[TBL] [Abstract][Full Text] [Related]
33. Gram-positive resistance: pathogens, implications, and treatment options: insights from the Society of Infectious Diseases Pharmacists.
Akins RL; Haase KK
Pharmacotherapy; 2005 Jul; 25(7):1001-10. PubMed ID: 16006278
[TBL] [Abstract][Full Text] [Related]
34. Antimicrobial-resistant gram-positive bacteria in PD peritonitis and the newer antibiotics used to treat them.
Salzer W
Perit Dial Int; 2005; 25(4):313-9. PubMed ID: 16022084
[TBL] [Abstract][Full Text] [Related]
35. Antibiotic resistance among clinically important gram-positive bacteria in the UK.
Johnson AP
J Hosp Infect; 1998 Sep; 40(1):17-26. PubMed ID: 9777517
[TBL] [Abstract][Full Text] [Related]
36. Quinupristin/dalfopristin.
Blondeau JM; Sanche SE
Expert Opin Pharmacother; 2002 Sep; 3(9):1341-64. PubMed ID: 12186626
[TBL] [Abstract][Full Text] [Related]
37. Novel antibacterial agents for the treatment of serious Gram-positive infections.
Abbanat D; Macielag M; Bush K
Expert Opin Investig Drugs; 2003 Mar; 12(3):379-99. PubMed ID: 12605562
[TBL] [Abstract][Full Text] [Related]
38. Antibiotic resistance in bacteria. A current and future problem.
Liu HH
Adv Exp Med Biol; 1999; 455():387-96. PubMed ID: 10599374
[TBL] [Abstract][Full Text] [Related]
39. Pharmacoeconomics of treatment with the newer anti-Gram-positive agents.
Wang L; Barrett JF
Expert Opin Pharmacother; 2006 May; 7(7):885-97. PubMed ID: 16634711
[TBL] [Abstract][Full Text] [Related]
40. New antibiotics for infections caused by resistant organisms.
McKinnon PS; Tam VH
Support Care Cancer; 2001 Jan; 9(1):8-10. PubMed ID: 11147147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
